Skip to content

English

繁體中文

syneuRx-logo
  • About
    • Mission
    • Leadership Team
    • Major Milestone
    • Contact
  • Service
    • New Drug Development
  • Research
    • Antiviral Platform
    • NMDA Platform
    • Pipeline
  • Trials
    • SNA11
    • SNG12
    • SND12
  • PRODUCT
  • Newsroom
    • Press Release
    • Publication
    • Media
  • About
    • Mission
    • Leadership Team
    • Major Milestone
    • Contact
  • Service
    • New Drug Development
  • Research
    • Antiviral Platform
    • NMDA Platform
    • Pipeline
  • Trials
    • SNA11
    • SNG12
    • SND12
  • PRODUCT
  • Newsroom
    • Press Release
    • Publication
    • Media

Press Release

ALL

2022

2021

2020~2015

Dec 08, 2022

SyneuRx CEO Emil Tsai Named Fellow of National Academy of Inventors

July 31, 2022

SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

July 25, 2022

Dr. Joseph T. Coyle Named Chair of SyneuRx’s Scientific Advisory Board

Apr 13, 2022

SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

Jan 06, 2022

SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants

Privacy Policy

Terms of Use

Contact

About

  • Mission
  • Leadership Team
  • Major Milestone

Research

  • Antiviral Platform
  • NMDA Platform
  • Pipeline

Trials

  • SNA11
  • SNG12
  • SND12

Newsroom

  • Press Release
  • Publication
  • Media
SyneuRx International (Taiwan) Corp.
Copyrights © 2013 SyneuRx Corp. All rights reserved.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.okPrivacy policy